DENVER, Jan. 26, 2022 /PRNewswire/ -- Infermedica, a leading digital health company, specializing in AI-powered solutions for symptom analysis and patient triage, today announces a $30 million Series B funding round, led by One Peak, and supported by previous investors: Karma Ventures, European Bank for Reconstruction and Development, Heal Capital, and Inovo Venture Partners. The new investment – which follows a Series A funding round just over a year ago – brings the company's total funding to $44 million. The capital will be used to support Infermedica in tackling some of the biggest issues facing healthcare through further development of their Medical Guidance Platform (MGP) and adding new modules to cover the full primary care journey. Infermedica will also increase their global commercial presence and expand their international, remote-first team of industry and medical experts.

More on Colorado Desk

• TSWHZC Platform Combines Automated Portfolio Management with Proof of Reserves for Brazil Market Entry
• AureaVault Positions Digital Asset Infrastructure for Shifting Monetary Policy Environment
• JQRBT Unveils High-Speed Trading Infrastructure Designed for Growing Institutional Crypto Market
• Denver Welcomes Year Three of MICHELIN Guide Colorado Awards with the State's First Two Starred Restaurant, Three New One Starred Restaurants, New Recommended and Three New Special Award Winners
• Boulder Homeowners Encouraged to Paint Before Move-In for a Healthier, More Beautiful Start

"We are incredibly excited to back the Infermedica team as we share their vision of making healthcare more accessible and affordable by automating primary care. We have been particularly impressed with Infermedica's clinical safety and accuracy, best-in-class user experience, ease of deployment, and customer service. We believe the company has all the ingredients in place to become the global standard for using AI to support patients and healthcare providers in all steps of the primary care journey and we look forward to supporting Infermedica in its next phase of explosive growth."

---

Show All News | Report Violation